Skip to main content
    A

    AptarGroup Inc (ATR)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $143.15
    +0.06 (+0.04%)

    Market Cap: $9.07B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    AptarGroup Inc (ATR) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    AptarGroup (ATR) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, AptarGroup reported EPS of $1.52, above the $1.46 estimate. It beat the EPS estimate in each of the last 17 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    85%(34/40)
    Avg Surprise
    +6.20%
    Streak
    17 Q

    Upcoming Estimates

    Reports Feb 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.44
    Range$1.38 - $1.51
    10 analysts
    Revenue Consensus
    $991.30M
    Range$939.12M - $1.06B
    9 analysts
    Reports Apr 29, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$1.35
    Range$1.31 - $1.38
    5 analysts
    EPS Revisions
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$1.39-2.8%
    60d ago$1.39-2.8%
    30d ago$1.39-2.8%
    7d ago$1.34+0.6%
    Current$1.35
    Revenue Consensus
    $1.01B
    Range$985.79M - $1.03B
    4 analysts

    Next Report

    ATR has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 15.2% above the $1.25 reported for the quarter ended Dec 31, 2025.

    ATR Earnings Call

    The latest ATR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, ATR beat 34, missed 3 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $1.02B, up 6.1% from $961.13M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.52$1.46$1.45 - $1.49+4.11%Beat-6.2%80 up, 1 downOct 29, 2026$1.02B
    Jun 30, 2026$1.42$1.34$1.33 - $1.38+5.97%Beat-14.5%7N/AJul 30, 2026$1.03B
    Mar 31, 2026$1.19$1.15$1.14 - $1.18+3.48%Beat-0.8%70 up, 3 downApr 30, 2026$982.87M
    Dec 31, 2025$1.25$1.23$1.20 - $1.27+1.63%Beat-17.8%70 up, 2 downFeb 5, 2026$962.74M
    Sep 30, 2025$1.62$1.57$1.54 - $1.59+3.18%Beat+8.7%62 up, 0 downOct 30, 2025$961.13M
    Jun 30, 2025$1.66$1.59$1.57 - $1.60+4.40%Beat+21.2%50 up, 2 downJul 31, 2025$966.01M
    Mar 31, 2025$1.20$1.16$1.13 - $1.19+3.45%Beat-4.8%61 up, 1 downMay 1, 2025$887.30M
    Dec 31, 2024$1.52$1.26$1.22 - $1.28+20.63%Beat+25.6%60 up, 3 downFeb 6, 2025$848.09M
    Sep 30, 2024$1.49$1.42$1.41 - $1.43+4.93%Beat+7.2%51 up, 0 downOct 24, 2024$909.29M
    Jun 30, 2024$1.37$1.35$1.34 - $1.39+1.48%Beat+11.4%50 up, 0 downJul 25, 2024$910.06M
    Mar 31, 2024$1.26$1.15$1.11 - $1.18+9.57%Beat+32.6%50 up, 0 downApr 25, 2024$915.45M
    Dec 31, 2023$1.21$1.12$1.10 - $1.13+8.04%Beat+31.5%50 up, 0 downFeb 8, 2024$838.48M
    Sep 30, 2023$1.39$1.27$1.25 - $1.29+9.45%Beat+46.3%51 up, 1 downOct 25, 2023$893.00M
    Jun 30, 2023$1.23$1.14$1.11 - $1.16+7.89%Beat+28.1%62 up, 0 downJul 27, 2023$895.91M
    Mar 31, 2023$0.95$0.90$0.88 - $0.92+5.56%Beat-1.0%70 up, 0 downApr 27, 2023$860.07M
    Dec 31, 2022$0.92$0.79$0.78 - $0.82+16.46%Beat-1.1%81 up, 0 downFeb 16, 2023$795.91M
    Sep 30, 2022$0.95$0.94$0.87 - $1.00+1.06%Beat+1.1%90 up, 2 downOct 27, 2022$836.86M
    Jun 30, 2022$0.96$0.96$0.90 - $1.010.00%In line+5.5%90 up, 1 downJul 28, 2022$844.54M
    Mar 31, 2022$0.96$0.96$0.93 - $0.980.00%In line-11.9%90 up, 2 downApr 28, 2022$844.93M
    Dec 31, 2021$0.93$0.91$0.88 - $0.94+2.20%Beat+1.1%90 up, 0 downFeb 17, 2022$813.99M
    Sep 30, 2021$0.94$0.94$0.91 - $0.970.00%In line-6.0%10N/AOct 28, 2021$825.44M
    Jun 30, 2021$0.91$0.97$0.92 - $1.02-6.19%Miss+13.7%10N/AJul 29, 2021$811.03M
    Mar 31, 2021$1.09$0.90$0.84 - $0.94+21.11%Beat+17.2%10N/AApr 29, 2021$776.75M
    Dec 31, 2020$0.92$0.90$0.88 - $0.94+2.22%Beat+15.0%10N/AFeb 18, 2021$749.33M
    Sep 30, 2020$1.00$0.84$0.80 - $0.88+19.05%Beat+7.5%10N/AOct 29, 2020$759.15M
    Jun 30, 2020$0.80$0.66$0.57 - $0.76+21.21%Beat-30.4%9N/AJul 30, 2020$699.30M
    Mar 31, 2020$0.93$0.87$0.83 - $0.92+6.90%Beat-13.1%9N/AApr 30, 2020$721.55M
    Dec 31, 2019$0.80$0.78$0.76 - $0.80+2.56%Beat-13.0%9N/AFeb 20, 2020$671.33M
    Sep 30, 2019$0.93$0.95$0.94 - $0.98-2.11%Miss-6.1%11N/AOct 31, 2019$701.28M
    Jun 30, 2019$1.15$1.13$1.12 - $1.15+1.77%Beat+5.5%12N/AJul 31, 2019$742.66M
    Mar 31, 2019$1.07$0.98$0.97 - $1.00+9.18%Beat+8.1%11N/AApr 30, 2019$744.46M
    Dec 31, 2018$0.92$0.85$0.83 - $0.86+8.24%Beat+13.6%11N/AFeb 20, 2019$685.03M
    Sep 30, 2018$0.99$0.93$0.90 - $0.95+6.45%Beat+28.6%11N/ANov 1, 2018$665.77M
    Jun 30, 2018$1.09$1.01$1.00 - $1.03+7.92%Beat+7.9%11N/AJul 26, 2018$710.61M
    Mar 31, 2018$0.99$0.93$0.91 - $0.94+6.45%Beat+22.2%9N/AApr 26, 2018$703.35M
    Dec 31, 2017$0.81$0.70$0.68 - $0.72+15.71%Beat+17.4%9N/AFeb 12, 2018$625.89M
    Sep 30, 2017$0.77$0.80$0.78 - $0.82-3.75%Miss-6.1%9N/AOct 26, 2017$624.33M
    Jun 30, 2017$1.01$0.96$0.94 - $1.01+5.21%Beat+11.0%10N/AJul 27, 2017$617.75M
    Mar 31, 2017$0.81$0.75N/A+8.00%Beat+14.1%N/AN/AApr 27, 2017$601.32M
    Dec 31, 2016$0.69$0.66N/A+4.55%Beat+3.0%N/AN/AFeb 9, 2017$538.87M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $5.73, up 1.6% from the year before. It was $3.13 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$5.73+1.6%
    Dec 31, 2024$5.64+18.0%
    Dec 31, 2023$4.78+26.1%
    Dec 31, 2022$3.79-2.1%
    Dec 31, 2021$3.87+6.0%
    Dec 31, 2020$3.65-7.6%
    Dec 31, 2019$3.95N/A
    Dec 31, 2018$3.99+17.4%
    Dec 31, 2017$3.40+8.6%
    Dec 31, 2016$3.13N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,800 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,76412
    2026Q2Jun 30, 20266,62110
    2026Q1Mar 31, 20266,53012
    2025Q4Dec 31, 20257,53311
    2025Q3Sep 30, 20256,59911
    2025Q2Jun 30, 20256,4929
    2025Q1Mar 31, 20256,85310
    2024Q4Dec 31, 20246,8759

    2026Q3 Earnings Call

    Opening remarks

    Mary Skafidas Senior Vice President, Investor Relations and Communications Hello, everyone. Good morning, and thanks for being with us on our call today. Joining me on today's call are Gael Touya, President and CEO, and Vanessa Kanu, Executive Vice President and CFO. Our press release and accompanying slide deck have been posted on our website under the Investor Relations page. During this call, we will be discussing certain non-GAAP financial measures. These measures are reconciled to the most directly comparable GAAP financial measure, and the reconciliations are set forth in the press release. Please refer to the press release disseminated yesterday for reconciliations of non-GAAP measures to the most comparable GAAP measures discussed during this earnings call. As always, we will post a replay of this call on our website. I would now like to turn the conference call over to Gael.

    Gael Touya President and CEO Thank you, Mary, and good morning, everyone. I'm pleased to join you today for my first earnings call as CEO of Aptar. I will touch on the quarter briefly and then turn it over to Vanessa to add more details. Our results in the quarter demonstrate the underlying strength of our businesses, with 5% core sales growth across all three segments and adjusted earnings per share at the higher end of our guidance range. Our adjusted EBITDA margin of 21.3% remained within our long-term target range, despite emergency medicine destocking and the associated mix impact. In Pharma, while the anticipated reduction in emergency medicine sales continues to affect our growth rate, the underlying business remains strong. Results were driven by broad-based demand across a number of end markets in each of our divisions. This breadth is important. Our Pharma growth opportunities are not dependent on one product or one therapeutic category. It reflects the depth of our portfolio, innovation pipeline, and the increasingly important role Aptar plays with customers across the drug development cycle. Our ambition is to continue moving forward, becoming the partner of choice for our customers through our technology, scientific expertise, services, and regulatory capabilities. Beauty also delivered strong top-line growth in the quarter, with strong demand from a number of end markets, including prestige fragrance and color cosmetics. But looking at profitability, I want to be clear. Sales growth alone is not our objective. Our goal is to convert the strong demand for our products into more consistent profitability. We have excellent technology, strong customer relationships, and leading positions in attractive categories. At the same time, the margin performance, mostly in North America, is not where it needs to be. Closures also delivered double-digit core sales growth, reflecting strong demand in beverage and food and continued momentum from innovation.

    Frequently Asked Questions About ATR

    When is AptarGroup's next earnings date?

    AptarGroup's next earnings report is expected for Feb 3, 2027.

    Did ATR beat earnings estimates last quarter?

    Yes. AptarGroup reported EPS of $1.52 for the quarter ended Sep 30, 2026, above the $1.46 estimate, a 4.11% surprise.

    What EPS do analysts expect from ATR next quarter?

    The consensus EPS estimate for AptarGroup for the quarter ending Dec 31, 2026 is $1.44 from 10 analysts, with estimates from $1.38 to $1.51.

    How often does ATR beat earnings estimates?

    AptarGroup beat the EPS estimate in each of the last 17 quarters, with an average surprise of +6.55%.